An article in the Philadelphia Inquirer highlights the growing promise of drugs known as immune checkpoint blockers for the treatment of melanoma. The drugs, the article says, "make cancer the roadkill of immune systems. "Imagine a car at the top of the hill that you want to make go," said Robert Vonderheide, MD, DPhil, associate director for Translational Research in the Abramson Cancer Center. "You have two options. Either press the gas pedal or release the brakes. These drugs are designed to cut the brakes as a way of getting the immune system to move." Tara Gangadhar, MD, an assistant professor in the division of Hematology-Oncology, and James Riley, an research associate professor of Microbiology are both quoted in the story, along with two patients who have been treated with these novel agents in the Abramson Cancer Center.
Read the entire Philadelphia Inquirer article